4 results
Approved WMOCompleted
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
Approved WMOCompleted
To determine the safety and efficacy of Dimebon in patients with mild-to-moderate Huntington Disease
Approved WMOCompleted
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
Approved WMOCompleted
Correcting the causative factors of intertrigo is critical. Take steps to eliminate friction, heat, and maceration by keeping folds cool and dry. The goals of pharmacotherapy for intertrigo are to reduce morbidity and to prevent complications. To…